Ewing's Family of Tumors disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: EWN002 MIFTS: 49	Ewing's Family of Tumors Categories: Rare diseases, Genetic diseases, Bone diseases, Neuronal diseases
Genes Tissues Related diseases Publications Pathways Drugs Download Expand all tables

Sources

Aliases & Classifications for Ewing's Family of Tumors

MalaCards integrated aliases for Ewing's Family of Tumors:

Name: Ewing's Family of Tumors ⁴⁹

Neuroectodermal Tumor, Primitive ⁶⁹

Primitive Neuroectodermal Tumor ⁴⁹

Ewing Family of Tumors ⁴⁹

Ewing’s Tumor of Bone ⁴⁹

Extraosseous Ewing’s ⁴⁹

Askin’s Tumor ⁴⁹

Classifications:

MalaCards categories:
Global: Rare diseases Genetic diseases
Anatomical: Bone diseases Neuronal diseases

See all MalaCards categories (disease lists)

Sources

Summaries for Ewing's Family of Tumors

MalaCards based summary : Ewing's Family of Tumors, also known as neuroectodermal tumor, primitive, is related to ewing sarcoma and sarcoma. An important gene associated with Ewing's Family of Tumors is EWSR1 (EWS RNA Binding Protein 1), and among its related pathways/superpathways are GPCR Pathway and PEDF Induced Signaling. The drugs Vincristine and Paclitaxel have been mentioned in the context of this disorder. Affiliated tissues include bone, nk cells and t cells, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Sources

Related Diseases for Ewing's Family of Tumors

Diseases related to Ewing's Family of Tumors via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 111)

#	Related Disease	Score	Top Affiliating Genes
1	ewing sarcoma	30.7	CDKN2A CSF3 EWSR1 FLI1 KIT KITLG
2	sarcoma	30.7	EWSR1 FLI1 KIT RB1
3	extraosseous ewing's sarcoma	12.6
4	askin's tumor	12.5
5	supratentorial primitive neuroectodermal tumor	12.5
6	cerebral primitive neuroectodermal tumor	12.4
7	intracranial primitive neuroectodermal tumor	12.4
8	extraosseous ewings sarcoma-primitive neuroepithelial tumor	11.6
9	kaposiform hemangioendothelioma	10.5	FLI1 MTOR
10	indolent systemic mastocytosis	10.4	KIT KITLG
11	cutaneous mastocytosis	10.4	KIT KITLG
12	transient erythroblastopenia of childhood	10.4	EPO KITLG
13	kidney fibrosarcoma	10.4	EPO EWSR1
14	aggressive systemic mastocytosis	10.4	KIT KITLG
15	uterine body mixed cancer	10.3	ERBB2 KIT
16	toxic optic neuropathy	10.3	EPO ERBB2
17	breast adenoid cystic carcinoma	10.3	ERBB2 KIT
18	urticaria pigmentosa	10.3	KIT KITLG
19	vulvar seborrheic keratosis	10.3	CDKN2A MTOR
20	acquired polycythemia	10.3	EPO EPOR
21	myxoid chondrosarcoma	10.2	CDKN2B EWSR1
22	cutaneous solitary mastocytoma	10.2	KIT KITLG
23	malignant mesenchymoma	10.2	CDK4 EWSR1 KIT
24	breast papillomatosis	10.2	CDKN2A ERBB2
25	erythrocytosis, familial, 2	10.2	EPO EPOR
26	connective tissue cancer	10.2	CDK4 EWSR1 KIT
27	histiocytoma	10.2	CDK4 EWSR1 KIT
28	fallopian tube endometrioid adenocarcinoma	10.2	CDKN2A ERBB2
29	rhabdomyosarcoma	10.2
30	infiltrating angiolipoma	10.2	CDK4 CDKN2A
31	vulval paget's disease	10.2	CDKN2A ERBB2
32	desmoplastic small round cell tumor	10.2	CSF3 EWSR1 FLI1
33	neonatal anemia	10.2	EPO EPOR
34	vulva adenocarcinoma	10.2	CDKN2A ERBB2
35	adenoid basal cell carcinoma	10.1	CDKN2A KIT
36	primary polycythemia	10.1	EPO EPOR
37	spindle cell liposarcoma	10.1	CDK4 KIT
38	skin sarcoma	10.1	CDK4 CDKN2B EWSR1
39	acute erythroid leukemia	10.1	EPO EPOR FLI1
40	doxorubicin induced cardiomyopathy	10.1	CSF3 EPOR
41	acral lentiginous melanoma	10.1	CDKN2A KIT
42	polycythemia	10.1	EPO EPOR KITLG
43	luminal breast carcinoma	10.1	ERBB2 MTOR
44	oral leukoplakia	10.1	CDKN2A ERBB2
45	plasmablastic lymphoma	10.1	CDKN2A MTOR
46	ischemic fasciitis	10.1	CDK4 CDKN2A
47	tenosynovial giant cell tumor	10.0	CDKN2A CDKN2B
48	spindle cell lipoma	10.0	CDK4 RB1
49	thyroid lymphoma	10.0	CDKN2A CDKN2B
50	neurofibroma	10.0	CDKN2A KIT KITLG

Graphical network of the top 20 diseases related to Ewing's Family of Tumors:

Sources

Symptoms & Phenotypes for Ewing's Family of Tumors

GenomeRNAi Phenotypes related to Ewing's Family of Tumors according to GeneCards Suite gene sharing:

²⁵ (show all 29)

#	Description	GenomeRNAi Source Accession	Score	Top Affiliating Genes
1	Increased shRNA abundance (Z-score > 2)	GR00366-A-102	10.16	KIT
2	Increased shRNA abundance (Z-score > 2)	GR00366-A-105	10.16	MTOR EWSR1
3	Increased shRNA abundance (Z-score > 2)	GR00366-A-11	10.16	MTOR
4	Increased shRNA abundance (Z-score > 2)	GR00366-A-115	10.16	CDK4
5	Increased shRNA abundance (Z-score > 2)	GR00366-A-126	10.16	EWSR1
6	Increased shRNA abundance (Z-score > 2)	GR00366-A-137	10.16	EWSR1
7	Increased shRNA abundance (Z-score > 2)	GR00366-A-140	10.16	EWSR1
8	Increased shRNA abundance (Z-score > 2)	GR00366-A-146	10.16	EWSR1
9	Increased shRNA abundance (Z-score > 2)	GR00366-A-152	10.16	EWSR1 KIT
10	Increased shRNA abundance (Z-score > 2)	GR00366-A-157	10.16	KIT
11	Increased shRNA abundance (Z-score > 2)	GR00366-A-16	10.16	MTOR
12	Increased shRNA abundance (Z-score > 2)	GR00366-A-164	10.16	EWSR1
13	Increased shRNA abundance (Z-score > 2)	GR00366-A-170	10.16	KIT
14	Increased shRNA abundance (Z-score > 2)	GR00366-A-19	10.16	EWSR1
15	Increased shRNA abundance (Z-score > 2)	GR00366-A-21	10.16	CDK4
16	Increased shRNA abundance (Z-score > 2)	GR00366-A-30	10.16	KIT
17	Increased shRNA abundance (Z-score > 2)	GR00366-A-42	10.16	CDK4 KIT MTOR EWSR1
18	Increased shRNA abundance (Z-score > 2)	GR00366-A-46	10.16	CDK4
19	Increased shRNA abundance (Z-score > 2)	GR00366-A-52	10.16	EWSR1
20	Increased shRNA abundance (Z-score > 2)	GR00366-A-73	10.16	MTOR
21	Increased shRNA abundance (Z-score > 2)	GR00366-A-81	10.16	EWSR1
22	Increased shRNA abundance (Z-score > 2)	GR00366-A-85	10.16	MTOR KIT CDK4
23	Increased shRNA abundance (Z-score > 2)	GR00366-A-9	10.16	KIT
24	Increased shRNA abundance (Z-score > 2)	GR00366-A-99	10.16	KIT EWSR1
25	Decreased substrate adherent cell growth	GR00193-A-1	9.7	KIT
26	Decreased substrate adherent cell growth	GR00193-A-2	9.7	CDK4 KIT MTOR
27	Decreased substrate adherent cell growth	GR00193-A-3	9.7	CDK4
28	Decreased substrate adherent cell growth	GR00193-A-4	9.7	CDK4 KIT
29	Increased transferrin (TF) endocytosis	GR00363-A	9.32	CDKN2A CDKN2B EPO KITLG EPOR MTOR

MGI Mouse Phenotypes related to Ewing's Family of Tumors:

⁴³ (show all 23)

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	cellular	MP:0005384	10.38	CDK4 CDKN2B CDKN2A KIT FLI1 KITLG
2	cardiovascular system	MP:0005385	10.35	CDK4 CDKN2A KIT FLI1 KITLG RB1
3	hematopoietic system	MP:0005397	10.35	CDKN2B CDKN2A CSF3 EPO CDK4 FLI1
4	immune system	MP:0005387	10.33	CDKN2B CDKN2A CSF3 CDK4 FLI1 KITLG
5	homeostasis/metabolism	MP:0005376	10.3	CDKN2A CDK4 CDKN2B KITLG KIT RB1
6	embryo	MP:0005380	10.29	CDKN2A EPO CDK4 FLI1 KITLG KIT
7	endocrine/exocrine gland	MP:0005379	10.28	CDK4 CDKN2B CDKN2A KIT FLI1 KITLG
8	growth/size/body region	MP:0005378	10.27	CDKN2A CDK4 FAS KIT FLI1 KITLG
9	mortality/aging	MP:0010768	10.27	CDK4 CDKN2B CDKN2A KIT FLI1 KITLG
10	integument	MP:0010771	10.24	CDKN2B CDKN2A CSF3 CDK4 KITLG KIT
11	liver/biliary system	MP:0005370	10.16	CDK4 CDKN2A FLI1 KITLG KIT RB1
12	digestive/alimentary	MP:0005381	10.14	CDKN2A CDK4 KITLG FAS KIT RB1
13	nervous system	MP:0003631	10.13	CDK4 CDKN2A KITLG KIT FLI1 RB1
14	neoplasm	MP:0002006	10.11	CDKN2B CDKN2A CDK4 FLI1 KITLG KIT
15	muscle	MP:0005369	10.08	CDK4 CDKN2A KIT FLI1 RB1 MTOR
16	limbs/digits/tail	MP:0005371	10	FAS KIT KITLG RB1 EPO ERBB2
17	normal	MP:0002873	9.97	CDK4 FAS KIT RB1 MTOR ERBB2
18	no phenotypic analysis	MP:0003012	9.88	CDKN2A CDKN2B KIT RB1 MTOR EPOR
19	pigmentation	MP:0001186	9.8	CDK4 CDKN2A KIT KITLG RB1 FAS
20	renal/urinary system	MP:0005367	9.8	CDK4 CDKN2B CSF3 KIT RB1 MTOR
21	reproductive system	MP:0005389	9.76	CDKN2A CDK4 CDKN2B KITLG FAS KIT
22	respiratory system	MP:0005388	9.56	CDKN2A KIT RB1 MTOR EPO EPOR
23	skeleton	MP:0005390	9.23	CDKN2A FAS KIT KITLG RB1 MTOR

Sources

Drugs & Therapeutics for Ewing's Family of Tumors

Drugs for Ewing's Family of Tumors (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 920)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Vincristine

Approved, Investigational

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

2068-78-2, 57-22-7

5978

Paclitaxel

Approved, Vet_approved

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

33069-62-4

36314

Etoposide

Approved

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

33419-42-0

36462

Cisplatin

Approved

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

15663-27-1

2767 441203 84093

Methotrexate

Approved

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

1959-05-2, 59-05-2

126941

Carboplatin

Approved

Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1

41575-94-4

10339178 38904 498142

Cyclophosphamide

Approved, Investigational

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

50-18-0, 6055-19-2

2907

Aminolevulinic acid

Approved

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

106-60-5

137

Sorafenib

Approved, Investigational

Phase 4,Phase 3,Phase 2,Phase 1

284461-73-0

216239 406563

Octreotide

Approved, Investigational

Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable

83150-76-9

6400441 383414

Hydrocortisone

Approved, Vet_approved

Phase 4,Phase 2

50-23-7

657311 5754

Miconazole

Approved, Investigational, Vet_approved

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

22916-47-8

4189

Mesna

Approved, Investigational

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

3375-50-6

598

Dacarbazine

Approved, Investigational

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

4342-03-4

5351166

Imiquimod

Approved, Investigational

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

99011-02-6

57469

Everolimus

Approved

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

159351-69-6

6442177

Temozolomide

Approved, Investigational

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

85622-93-1

5394

Thiotepa

Approved, Investigational

Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1

52-24-4

5453

Lenograstim

Approved, Investigational

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

135968-09-1

Triamcinolone

Approved, Vet_approved

Phase 4,Phase 2,Phase 3,Not Applicable

124-94-7

31307

Sunitinib

Approved, Investigational

Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable

341031-54-7, 557795-19-4

5329102

Ranibizumab

Approved

Phase 4,Phase 2,Phase 3,Phase 1

347396-82-1

459903

Aldesleukin

Approved

Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1

110942-02-4, 85898-30-2

Vindesine

Approved, Investigational

Phase 4,Phase 3,Phase 2,Not Applicable

53643-48-4, 59917-39-4

40839

Prednisone

Approved, Vet_approved

Phase 4,Phase 3,Phase 2

53-03-2

5865

Sirolimus

Approved, Investigational

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

53123-88-9

46835353 6436030 5284616

Trametinib

Approved

Phase 4,Phase 3,Phase 2,Phase 1

871700-17-3

11707110

nivolumab

Approved

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

946414-94-4

Somatostatin

Approved, Investigational

Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1

38916-34-6, 51110-01-1

53481605

Diazoxide

Approved

Phase 4,Phase 3,Phase 2

364-98-7

3019

Gefitinib

Approved, Investigational

Phase 4,Phase 2,Phase 1,Not Applicable

184475-35-2

123631

Dasatinib

Approved, Investigational

Phase 4,Phase 1,Phase 2

302962-49-8

3062316

Valproic Acid

Approved, Investigational

Phase 4,Phase 2,Phase 3,Phase 1

99-66-1

3121

Doxazosin

Approved

Phase 4,Phase 3

74191-85-8

3157

Piracetam

Approved, Investigational

Phase 4,Phase 2

7491-74-9

Etanercept

Approved, Investigational

Phase 4,Phase 2

185243-69-0

Bortezomib

Approved, Investigational

Phase 4,Phase 2,Phase 1

179324-69-7

387447 93860

lanreotide

Approved

Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1

108736-35-2

Itraconazole

Approved, Investigational

Phase 4,Phase 1

84625-61-6

55283

Benzocaine

Approved, Investigational

Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1

1994-09-7, 94-09-7

2337

Phenoxybenzamine

Approved

Phase 4,Phase 3

59-96-1

4768

Pancrelipase

Approved, Investigational

Phase 4,Phase 2,Phase 1,Not Applicable

53608-75-6

Vorinostat

Approved, Investigational

Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1

149647-78-9

5311

Ramucirumab

Approved, Investigational

Phase 4,Phase 2,Phase 1

947687-13-0

Dabrafenib

Approved, Investigational

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

44462760 44516822

Palbociclib

Approved, Investigational

Phase 4,Phase 2,Phase 1

571190-30-2

5330286 11431660 5005498

Olaparib

Approved

Phase 4,Phase 2,Phase 1

763113-22-0

23725625

Nicotine

Approved

Phase 4,Not Applicable

54-11-5

89594 942

Zinc

Approved, Investigational

Phase 4,Phase 1,Not Applicable

7440-66-6

32051 23994

Ritonavir

Approved, Investigational

Phase 4,Phase 2,Phase 1

155213-67-5

392622

Interventional clinical trials:

(show top 50) (show all 4855)

#	Name	Status	NCT ID	Phase	Drugs
1	Intravitreal Ranibizumab for the Prevention of Radiation Maculopathy Following Plaque Radiotherapy	Unknown status	NCT00540930	Phase 4	Ranibizumab
2	Standard Palliative Care Versus Standard Palliative Care Plus Polychemotherapy in Metastasized Malignant Melanoma	Unknown status	NCT00226473	Phase 4	Cisplatin, Vindesine, Dacarbazine (drugs)
3	Effect of Perioperative Glucocorticoid Replacement on Prognosis of Surgical Patients With Sellar Lesions	Unknown status	NCT02190994	Phase 4	Hydrocortisone;Prednisone
4	Efficacy of Prophylactic Itraconazole in High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation	Completed	NCT00336531	Phase 4	itraconazole
5	Extension Study to the Open-label, Multi-center, Expanded Access Study of Everolimus in Patients With Advanced Neuroendocrine Tumors	Completed	NCT01595009	Phase 4	RAD001
6	Somatuline Autogel Preference and Health Economy Study	Completed	NCT00681187	Phase 4	lanreotide (Autogel formulation)
7	Circulating Tumour Cells in Somatuline Autogel Treated NeuroEndocrine Tumours Patients	Completed	NCT02075606	Phase 4	lanreotide acetate
8	CEV With/Without Periocular Carboplatin Chemotherapy for Extraocular Retinoblastoma	Completed	NCT02319486	Phase 4	carboplatin periocular injection;CEV chemotherapy
9	Phase 3 Trial in Subjects With Metastatic Melanoma Comparing 3 mg/kg Ipilimumab Versus 10 mg/kg Ipilimumab	Completed	NCT01515189	Phase 4
10	Can We Miss Pigmented Lesions in Psoriasis Patients?	Completed	NCT01053819	Phase 4	etanercept
11	Phenoxybenzamine Versus Doxazosin in PCC Patients	Completed	NCT01379898	Phase 4	Phenoxybenzamine;Doxazosin
12	Post-Operative Drainage Following Lymph Node Dissection	Completed	NCT00324272	Phase 4	Fibrin Sealant (Tisseel) used in the Experimental Arm.
13	Randomized Clinical Trial of Posterior Retroperitoneoscopic Adrenalectomy Versus Lateral Laparoscopic Adrenalectomy	Completed	NCT01959711	Phase 4
14	Standard Temodal (Temozolomide) Regimen Versus Standard Regimen Plus Early Postsurgery Temodal for Newly Diagnosed Glioblastoma Multiforme (Study P05572)	Completed	NCT00686725	Phase 4	Temozolomide
15	RAD001 With Paclitaxel and Carboplatin in First Line Treatment of Patients With Advanced Large Cell Lung Cancer With Neuroendocrine Differentiation	Completed	NCT01317615	Phase 4	RAD001;Paclitaxel;Carboplatin
16	Effect of Topical Imiquimod on Lentigo Maligna	Completed	NCT01161888	Phase 4	Imiquimod
17	Dolutegravir and Darunavir Evaluation in Adults Failing Therapy	Recruiting	NCT03017872	Phase 4	N(t)RTIs;Dolutegravir;Darunavir;Ritonavir
18	HeadStart4: Newly Diagnosed Children (<10 y/o) With Medulloblastoma and Other CNS Embryonal Tumors	Recruiting	NCT02875314	Phase 4	Induction;Single Cycle Intensive Chemotherapy;Tandem 3 Cycle Intensive Chemotherapy
19	A Study to Evaluate Patient Experience in the Therapy of Neuroendocrine Tumors Treated With Octreotide Long Acting Release Versus Lanreotide	Recruiting	NCT03289741	Phase 4	Octreotide;LAR Lanreotide
20	Study of Lanreotide in Metastatic or Recurrent Grade I-II Hindgut NET	Recruiting	NCT03083210	Phase 4	Lanreotide
21	Nonfunctional Pancreatic NET and PET Imaging	Recruiting	NCT02621541	Phase 4
22	Phase IV Study of the Safety and Efficacy of Everolimus in Adult Patients With Progressive pNET in China	Recruiting	NCT02842749	Phase 4	everolimus
23	Seizure Treatment in Glioma	Recruiting	NCT03048084	Phase 4	Levetiracetam;Valproic Acid
24	Neoadjuvant Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in Cutaneous Stage L-lll Melanoma	Recruiting	NCT02451488	Phase 4	GM-CSF
25	Gentamicin Treatment Prior to Schwannoma Surgery - No Residual Function	Recruiting	NCT02415257	Phase 4	Gentamicin
26	Gentamicin Treatment Prior to Schwannoma Surgery - Residual Function	Recruiting	NCT02379754	Phase 4	Gentamicins
27	Assessment of Optune Therapy for Patients With Newly Diagnosed Glioblastoma Using Advanced MRI	Recruiting	NCT03297125	Phase 4
28	Supra-early Post-Surgery Chemotherapy in the Treatment on GBM Patients	Recruiting	NCT02520635	Phase 4	supra-early TEMODAL® chemotherapy;standard TEMODAL® chemotherapy
29	Dabrafenib and/or Trametinib Rollover Study	Recruiting	NCT03340506	Phase 4	dabrafenib;trametinib
30	Photodynamic Therapy for Lentigo Maligna Using 5-aminolevulinic Acid Nanoemulsion as a Light Sensitizing Cream	Recruiting	NCT02685592	Phase 4	5-aminolevulinic acid nanoemulsion
31	Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in a Novartis-sponsored Study.	Recruiting	NCT01794793	Phase 4	Pasireotide
32	Radiolabeled Molecules for Medullary Thyroid Cancer	Recruiting	NCT01915485	Phase 4
33	A Study of Two Different Doses of Cabozantinib (XL184) in Progressive, Metastatic Medullary Thyroid Cancer	Recruiting	NCT01896479	Phase 4	Cabozantinib (XL184) 140 mg;Cabozantinib (XL184) 60 mg;Placebo tablet;Placebo capsule
34	Clinical Effectiveness of Serum Chromogranin A Levels on Diagnostic of Pancreatic Neuroendocrine Tumors	Active, not recruiting	NCT02759718	Phase 4
35	A Study Of The Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors	Active, not recruiting	NCT01525550	Phase 4	sunitinib
36	Immune Modulation Study in Patients With Metastatic Melanoma Treated With Anti-PD1 Monoclonal Antibodies	Active, not recruiting	NCT02626065	Phase 4	Nivolumab
37	TTT Versus TTT and Triamcinolone to Decrease Exudation in Choroidal Melanoma After Proton Beam Therapy	Active, not recruiting	NCT02379000	Phase 4	Triamcinolone Acetonide
38	A National Phase IV Study With Ipilimumab for Patients With Advanced Malignant Melanoma.	Active, not recruiting	NCT02068196	Phase 4	Ipilimumab
39	An Open-Label Study of Zelboraf (Vemurafenib) in Patients With Braf V600 Mutation Positive Metastatic Melanoma	Active, not recruiting	NCT01898585	Phase 4	Zelboraf
40	Stereotactic Body Radiotherapy for Head and Neck Tumors	Active, not recruiting	NCT01344356	Phase 4
41	G-CSF Alone or Combination With GM-CSF on Prevention and Treatment of Infection in Children With Malignant Tumor	Not yet recruiting	NCT02933333	Phase 4
42	Molecular Profiling and Matched Targeted Therapy for Patients With Metastatic Melanoma	Not yet recruiting	NCT02645149	Phase 4	Standard therapy or clinical trial;Matched targeted therapy;Trametinib and / or supportive care
43	Effect of Cytokine-induced Killer Cells for Advanced Malignant Gliomas	Not yet recruiting	NCT02496988	Phase 4	Temozolomide
44	HD IL-2 + Ipilimumab in Patients With Metastatic Melanoma	Terminated	NCT01856023	Phase 4	High Dose Interleukin-2;Ipilimumab
45	HD IL-2 + Vemurafenib in Patients With BRAF Mutation Positive Metastatic Melanoma	Terminated	NCT01683188	Phase 4	vemurafenib + HD IL-2
46	Post-approval Study of NovoTTF-100A in Recurrent GBM Patients	Terminated	NCT01756729	Phase 4
47	Pasireotide Treatment for Neuroendocrine Tumor	Withdrawn	NCT02779257	Phase 4	Pasireotide;Diazoxide
48	Combination Chemotherapy Plus Surgery and Radiation Therapy in Treating Patients With Ewing's Sarcoma	Unknown status	NCT00002516	Phase 3	cyclophosphamide;doxorubicin hydrochloride;etoposide;ifosfamide;mesna;vincristine sulfate
49	Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation, Radiation Therapy, and/or Surgery in Treating Patients With Ewing's Sarcoma	Unknown status	NCT00020566	Phase 3	busulfan;doxorubicin hydrochloride;etoposide;ifosfamide;melphalan;vincristine sulfate
50	Stem Cell Transplant for High Risk Central Nervous System (CNS) Tumors	Unknown status	NCT00179803	Phase 2, Phase 3

Search NIH Clinical Center for Ewing's Family of Tumors

Sources

Genetic Tests for Ewing's Family of Tumors

Sources

Anatomical Context for Ewing's Family of Tumors

MalaCards organs/tissues related to Ewing's Family of Tumors:

³⁸

Bone, Nk Cells, T Cells, Testes, Lung, Kidney, Brain

Sources

Publications for Ewing's Family of Tumors

Articles related to Ewing's Family of Tumors:

(show all 13)

#	Title	Authors	Year
1	High-dose chemotherapy and stem cell rescue for high-risk Ewing's family of tumors. ( 21342043 )	Rosenthal J....Pawlowska A.B.	2011
2	Ewing's family of tumors of the sinonasal tract and maxillary bone. ( 21107767 )	Hafezi S....Weinreb I.	2011
3	Immunophenotypic profile of biomarkers related to anti-apoptotic and neural development pathways in the Ewing's family of tumors (EFT) and their therapeutic implications. ( 17695539 )	Navarro S....Llombart-Bosch A.	2007
4	Single center experience of treatment of Ewing's family of tumors in Japan. ( 16437346 )	Yamada K....Takahashi M.	2006
5	Prognostic and therapeutic targets in the Ewing's family of tumors (PROTHETS). ( 17163151 )	Picci P....Rizzi A.	2006
6	High-dose therapy and stem-cell rescue for Ewing's family of tumors in second remission. ( 15781877 )	Marina N....Meyers P.A.	2005
7	EWS-FLI1 fusion protein up-regulates critical genes in neural crest development and is responsible for the observed phenotype of Ewing's family of tumors. ( 15930281 )	Hu-Lieskovan S....Triche T.J.	2005
8	Megatherapy and stem cell transplantation for Ewing's family of tumors: a critical review of current literature. ( 15125709 )	Kalambakas S.A....Feig S.A.	2004
9	Long-term event-free survival after intensive chemotherapy for Ewing's family of tumors in children and young adults. ( 12972518 )	Kolb E.A....Meyers P.A.	2003
10	Single center experience of a new intensive induction therapy for ewing's family of tumors: feasibility, toxicity, and stem cell mobilization properties. ( 12885818 )	Strauss S.J....Whelan J.S.	2003
11	Ewing's family of tumors involving structures related to the central nervous system: a review. ( 10742406 )	Hadfield M.G....Luo V.Y.	2000
12	Chemotherapy dose-intensification for pediatric patients with Ewing's family of tumors and desmoplastic small round-cell tumors: a feasibility study at St. Jude Children's Research Hospital. ( 10458232 )	Marina N.M....Meyer W.H.	1999
13	Ewing's family of tumors in adults: multivariate analysis of survival and long-term results of multimodality therapy in 182 patients. ( 9850016 )	Fizazi K....Nguyen B.B.	1998

Sources

Genes for Ewing's Family of Tumors

Genes related to Ewing's Family of Tumors (0 elite genes):

(show all 14)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Implication
1	EWSR1	EWS RNA Binding Protein 1	Protein Coding	18.2	GeneCards inferred via : Publications (show sections)
2	FLI1	Fli-1 Proto-Oncogene, ETS Transcription Factor	Protein Coding	18	GeneCards inferred via : Publications (show sections)
3	KITLG	KIT Ligand	Protein Coding	17.65	GeneCards inferred via : Publications (show sections)
4	MTOR	Mechanistic Target Of Rapamycin Kinase	Protein Coding	17.65	GeneCards inferred via : Publications (show sections)
5	FAS	Fas Cell Surface Death Receptor	Protein Coding	17.65	GeneCards inferred via : Publications (show sections)
6	ERBB2	Erb-B2 Receptor Tyrosine Kinase 2	Protein Coding	17.65	GeneCards inferred via : Publications (show sections)
7	CDK4	Cyclin Dependent Kinase 4	Protein Coding	17.65	GeneCards inferred via : Publications (show sections)
8	KIT	KIT Proto-Oncogene Receptor Tyrosine Kinase	Protein Coding	17.65	GeneCards inferred via : Publications (show sections)
9	EPOR	Erythropoietin Receptor	Protein Coding	17.65	GeneCards inferred via : Publications (show sections)
10	EPO	Erythropoietin	Protein Coding	17.65	GeneCards inferred via : Publications (show sections)
11	CDKN2B	Cyclin Dependent Kinase Inhibitor 2B	Protein Coding	17.65	GeneCards inferred via : Publications (show sections)
12	CDKN2A	Cyclin Dependent Kinase Inhibitor 2A	Protein Coding	17.65	GeneCards inferred via : Publications (show sections)
13	RB1	RB Transcriptional Corepressor 1	Protein Coding	17.65	GeneCards inferred via : Publications (show sections)
14	CSF3	Colony Stimulating Factor 3	Protein Coding	7.65	GeneCards inferred via : Publications (show sections)

Sources

Variations for Ewing's Family of Tumors

Sources

Expression for Ewing's Family of Tumors

Search GEO for disease gene expression data for Ewing's Family of Tumors.

Sources

Pathways for Ewing's Family of Tumors

Pathways related to Ewing's Family of Tumors according to GeneCards Suite gene sharing:

(show all 46)

#	Super pathways	Score	Top Affiliating Genes
1	GPCR Pathway ⁶⁰ Show member pathways Breast Cancer Regulation by Stathmin1 ⁶⁰ Estrogen Pathway ⁶⁰ NFAT in Immune Response ⁶⁰ P2Y Receptor Signaling ⁶⁰ Pancreatic Adenocarcinoma ⁶⁰ Paxillin Interactions ⁶⁰ Ras Pathway ⁶⁰	13.63	CDK4 CDKN2A CDKN2B EPOR ERBB2 KIT
2	PEDF Induced Signaling ⁶⁰ Show member pathways all-trans-Retinoic Acid Signaling in Brain ⁶⁰ Cytokine-cytokine receptor interaction ³⁶ Endothelin-1 Signaling Pathway ⁶⁰ Glucocorticoid Receptor Signaling ⁶⁰ IL-6 Pathway ⁶⁰ MIF Mediated Glucocorticoid Regulation ⁶⁰ MIF Regulation of Innate Immune Cells ⁶⁰ NFAT Signaling and Lymphocyte Interactions ⁶⁰ PGC1Alpha Pathway ⁶⁰ RAR-Gamma-RXR-Alpha Degradation ⁶⁰ STAT3 Pathway ⁶⁰	13.55	CSF3 EPO EPOR ERBB2 FAS KIT
3	ERK Signaling ⁶⁰ Show member pathways ILK Signaling ⁶⁰ MAPK Signaling ⁶⁰ Molecular Mechanisms of Cancer ⁶⁰ Rho Family GTPases ⁶⁰	13.47	CDK4 CDKN2A CDKN2B CSF3 EPOR ERBB2
4	Akt Signaling ⁶⁰ Show member pathways p38 Signaling ⁶⁰ Tec Kinases Signaling ⁶⁰	13.31	CSF3 EPOR ERBB2 FAS KIT KITLG
5	Cellular Senescence (REACTOME) ⁶² Show member pathways Cellular Senescence ⁶² Oxidative Stress Induced Senescence ⁶² Senescence-Associated Secretory Phenotype (SASP) ⁶²	13.05	CDK4 CDKN2A CDKN2B EPO MTOR RB1
6	Endometrial cancer ³⁶ Show member pathways Acute myeloid leukemia ³⁶ Binding of TCF/LEF-CTNNB1 to target gene promoters ⁶² Colorectal cancer ³⁶ EGFR tyrosine kinase inhibitor resistance ³⁶ Glioma ³⁶ Melanoma ³⁶ Non-small cell lung cancer ³⁶ Prostate cancer ³⁶ Signal transduction PTEN pathway ²¹ Signaling Pathways in Glioblastoma ¹ Thyroid cancer ³⁶	12.9	CDK4 CDKN2A CDKN2B ERBB2 KIT MTOR
7	Gastric cancer ³⁶ Show member pathways Breast cancer ³⁶ Hepatocellular carcinoma ³⁶	12.53	CDK4 CDKN2A CDKN2B ERBB2 KIT MTOR
8	Kaposi's sarcoma-associated herpesvirus infection ³⁶ Show member pathways Hepatitis B ³⁶	12.5	CDK4 FAS MTOR RB1
9	Mitotic G1-G1/S phases ⁶² Show member pathways G1 to S cell cycle control ¹ G1/S Transition ⁶²	12.5	CDK4 CDKN2A CDKN2B RB1
10	NF-kappaB Signaling ⁴	12.49	FAS FLI1 KIT KITLG
11	Relaxin signaling pathway ³⁶ Show member pathways Endocrine resistance ³⁶ Estrogen signaling pathway ³⁶ Relaxin receptors ⁶²	12.48	CDK4 CDKN2A ERBB2 MTOR RB1
12	PI3K-Akt signaling pathway ³⁶ Show member pathways Human papillomavirus infection ³⁶	12.43	CDK4 CSF3 EPO EPOR FAS KIT
13	HTLV-I infection ³⁶	12.37	CDK4 CDKN2A CDKN2B RB1
14	DNA Damage Response ¹ Show member pathways miRNA Regulation of DNA Damage Response ¹ p53 signaling pathway ³⁶	12.3	CDK4 CDKN2A FAS RB1
15	Cyclins and Cell Cycle Regulation ⁶⁰ Show member pathways Cell Cycle Control by BTG Proteins ⁶⁰ Cyclin D associated events in G1 ⁶² G1 Phase ⁶² G1-S Phase Transition ⁶⁰ Phosphorylation of proteins involved in G1/S transition by active Cyclin E-Cdk2 complexes ⁶²	12.29	CDK4 CDKN2A CDKN2B RB1
16	Jak-STAT signaling pathway (KEGG) ³⁶ Show member pathways B-Cell Development ⁶⁰ IL-7 Signaling Pathways and their Primary Biological Effects in Different Immune Cell Types ⁶¹ Interleukin-19, 20, 22, 24 ⁶² Jak/STAT Signaling Pathway ⁶¹	12.28	CSF3 EPO EPOR MTOR
17	Cell cycle ³⁶ ¹	12.25	CDK4 CDKN2A CDKN2B KITLG RB1
18	Viral carcinogenesis ³⁶	12.22	CDK4 CDKN2A CDKN2B RB1
19	MAPK Signaling: Mitogen Stimulation Pathway ⁶¹ Show member pathways Akt Signaling Pathway ⁶¹	12.15	CDK4 ERBB2 MTOR RB1
20	Cell cycle Role of SCF complex in cell cycle regulation ²¹ Show member pathways Cell cycle ESR1 regulation of G1/S transition ²¹ Cell cycle Regulation of G1/S transition (part 1) ²¹ Immune response MIF-JAB1 signaling ²¹	12.13	CDK4 CDKN2A CDKN2B RB1
21	Pathways in cancer ³⁶	12.09	CDK4 CDKN2A CDKN2B EPO EPOR ERBB2
22	Kit receptor signaling pathway ¹ Show member pathways IL-3 Signaling Pathway ¹ Signaling events mediated by Stem cell factor receptor (c-Kit) ¹	12.08	EPO EPOR KIT KITLG
23	Integrated Breast Cancer Pathway ¹	12.06	CDK4 MTOR RB1
24	Tyrosine Kinases / Adaptors ⁴	12.04	ERBB2 KIT KITLG
25	Cellular senescence (KEGG) ³⁶	12.03	CDK4 CDKN2A CDKN2B MTOR RB1
26	Chronic myeloid leukemia ³⁶ Show member pathways Pancreatic cancer ³⁶	11.99	CDK4 CDKN2A ERBB2 MTOR RB1
27	p53 Pathway (RnD) ⁶¹	11.97	CDK4 CDKN2A FAS MTOR
28	Hematopoietic Stem Cell Differentiation Pathways and Lineage-specific Markers ⁶¹	11.89	CSF3 EPO KIT KITLG
29	Senescence and Autophagy in Cancer ¹	11.88	CDKN2A MTOR RB1
30	Glioblastoma Multiforme ⁶⁰	11.86	CDK4 CDKN2A MTOR RB1
31	HIF-1 signaling pathway ³⁶	11.85	EPO ERBB2 MTOR
32	Small cell lung cancer ³⁶	11.81	CDK4 CDKN2B RB1
33	Jak-Stat Signaling Pathway (sino) ⁶³	11.77	EPO EPOR MTOR
34	Platinum drug resistance ³⁶	11.69	CDKN2A ERBB2 FAS
35	Human Thyroid Stimulating Hormone (TSH) signaling pathway ¹	11.66	CDK4 MTOR RB1
36	Central carbon metabolism in cancer ³⁶	11.62	ERBB2 KIT MTOR
37	Bladder cancer ³⁶ ¹	11.62	CDK4 CDKN2A ERBB2 RB1
38	Hematopoietic cell lineage ³⁶	11.54	CSF3 EPO EPOR KIT KITLG
39	Photodynamic therapy-induced AP-1 survival signaling. ¹	11.49	CDKN2A FAS RB1
40	Differentiation Pathway ¹	11.45	EPO KIT KITLG
41	Integrated Cancer Pathway ¹	11.41	CDK4 CDKN2B RB1
42	Hematopoietic Stem Cell Differentiation ¹	11.35	CSF3 EPO FLI1 KITLG
43	Oncogene Induced Senescence ⁶²	11.22	CDK4 CDKN2A CDKN2B
44	Inhibition of Ribosome Biogenesis by p14(ARF) ⁶⁰	11.04	CDKN2A RB1
45	G-protein signaling_Rap2B regulation pathway ²¹	10.96	CSF3 EPOR ERBB2 KIT KITLG
46	Regulation of KIT signaling ⁶²	10.89	KIT KITLG

Sources

GO Terms for Ewing's Family of Tumors

Biological processes related to Ewing's Family of Tumors according to GeneCards Suite gene sharing:

(show all 23)

#	Name	GO ID	Score	Top Affiliating Genes
1	signal transduction	GO:0007165	9.97	CDK4 EPO EPOR ERBB2 FAS KIT
2	positive regulation of gene expression	GO:0010628	9.89	CDKN2A ERBB2 KIT MTOR
3	regulation of transcription by RNA polymerase II	GO:0006357	9.89	EPO ERBB2 FLI1 KIT RB1
4	positive regulation of cell proliferation	GO:0008284	9.88	CDK4 CSF3 EPO KIT KITLG
5	cytokine-mediated signaling pathway	GO:0019221	9.79	CSF3 EPOR KIT
6	phosphatidylinositol phosphorylation	GO:0046854	9.73	ERBB2 KIT KITLG
7	phosphorylation	GO:0016310	9.73	CDK4 CDKN2A CDKN2B ERBB2 KIT MTOR
8	G1/S transition of mitotic cell cycle	GO:0000082	9.72	CDK4 CDKN2A RB1
9	positive regulation of peptidyl-tyrosine phosphorylation	GO:0050731	9.7	CSF3 KITLG MTOR
10	positive regulation of translation	GO:0045727	9.63	CDK4 ERBB2 MTOR
11	negative regulation of phosphorylation	GO:0042326	9.61	CDKN2A CDKN2B
12	positive regulation of Ras protein signal transduction	GO:0046579	9.6	EPO KITLG
13	response to hyperoxia	GO:0055093	9.58	CDK4 EPO
14	megakaryocyte development	GO:0035855	9.58	FLI1 KIT
15	positive regulation of MAP kinase activity	GO:0043406	9.58	ERBB2 KIT KITLG
16	embryonic hemopoiesis	GO:0035162	9.57	KIT KITLG
17	positive regulation of transcription by RNA polymerase III	GO:0045945	9.54	ERBB2 MTOR
18	somatic stem cell division	GO:0048103	9.51	CDKN2A KIT
19	cell cycle arrest	GO:0007050	9.46	CDKN2A CDKN2B MTOR RB1
20	ectopic germ cell programmed cell death	GO:0035234	9.43	KIT KITLG
21	positive regulation of protein kinase B signaling	GO:0051897	9.35	CSF3 ERBB2 KIT KITLG MTOR
22	negative regulation of immature T cell proliferation in thymus	GO:0033088	9.32	CDKN2A ERBB2
23	erythropoietin-mediated signaling pathway	GO:0038162	8.8	EPO EPOR KIT

Molecular functions related to Ewing's Family of Tumors according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	nucleotide binding	GO:0000166	9.73	CDK4 ERBB2 KIT MTOR
2	identical protein binding	GO:0042802	9.73	EPOR ERBB2 EWSR1 FAS MTOR RB1
3	Ras guanyl-nucleotide exchange factor activity	GO:0005088	9.54	ERBB2 KIT KITLG
4	cyclin-dependent protein serine/threonine kinase inhibitor activity	GO:0004861	9.32	CDKN2A CDKN2B
5	signal transducer, downstream of receptor, with protein tyrosine kinase activity	GO:0004716	9.16	ERBB2 KIT
6	phosphatidylinositol-4,5-bisphosphate 3-kinase activity	GO:0046934	9.13	ERBB2 KIT KITLG
7	kinase activity	GO:0016301	9.1	CDK4 CDKN2A CDKN2B ERBB2 KIT MTOR
8	protein binding	GO:0005515	10.22	CDK4 CDKN2A CDKN2B EPO EPOR ERBB2

Sources

Sources for Ewing's Family of Tumors

¹ BioSystems

² BitterDB

³ CDC

⁴ Cell Signaling Technology

⁵ ClinicalTrials

⁶ ClinVar

⁷ CNVD

⁸ Cochrane Library

⁹ Cosmic

¹⁰ dbSNP

¹¹ DGIdb

¹² Disease Ontology

¹³ diseasecard

¹⁴ DISEASES

¹⁵ DrugBank

¹⁶ ExPASy

¹⁷ FDA Approved Drugs

¹⁸ FMA

¹⁹ GeneAnalytics

²⁰ GeneCards

²¹ GeneGo (Thomson Reuters)

²² GeneHancer via GeneCards

²³ GeneReviews

²⁴ Genetics Home Reference

²⁵ GenomeRNAi

²⁶ GEO DataSets

²⁷ GO

²⁸ GTR

²⁹ HGMD

³⁰ HMDB

³¹ HPO

³² ICD10

³³ ICD10 via Orphanet

³⁴ ICD9CM

³⁵ IUPHAR

³⁶ KEGG

³⁷ LifeMap

³⁸ MalaCards

³⁹ MedGen

⁴⁰ MedlinePlus

⁴¹ MeSH

⁴² MESH via Orphanet

⁴³ MGI

⁴⁴ NCBI Bookshelf

⁴⁵ NCI

⁴⁶ NCIt

⁴⁷ NDF-RT

⁴⁸ NIH Clinical Center

⁴⁹ NIH Rare Diseases

⁵⁰ NINDS

⁵¹ Novoseek

⁵² Novus Biologicals

⁵³ OMIM

⁵⁴ OMIM via Orphanet

⁵⁵ Orphanet

⁵⁶ PathCards

⁵⁷ PharmGKB

⁵⁸ PubMed

⁵⁹ PubMed Health

⁶⁰ QIAGEN

⁶¹ R&D Systems

⁶² Reactome

⁶³ Sino Biological

⁶⁴ SNOMED-CT

⁶⁵ SNOMED-CT via HPO

⁶⁶ SNOMED-CT via Orphanet

⁶⁷ TGDB

⁶⁸ Tocris

⁶⁹ UMLS

⁷⁰ UMLS via Orphanet

⁷¹ UniProtKB/Swiss-Prot

⁷² Wikipedia